DRI Healthcare Crystallizes Ekterly at 1.5x, Fuels Next Phase of Royalty Deployment
Record Q2 results, Lumvoa approval, and a $178M put option create a powerful re-deployment arsenal for the royalty acquirer.
DHT-UN.TO · Earnings Call · 2026-08-10
A record quarter and a much-anticipated liquidity event
DRI Healthcare delivered a standout second quarter, with total income up 13% to $50.1 million and adjusted EBITDA jumping 40% to $42.6 million. The most transformative development, however, was the monetization of its Ekterly investment. Following Chiesi's acquisition of KalVista, DRI exercised its put option and received approximately $178 million in net repurchase proceeds, realizing a 1.5x return and a high-20s IRR for unitholders. As CEO Ali Hedayat noted, “we exercised our put option on Ekterly for a total net repurchase price of approximately $178 million, creating a significant and immediate realized return of 1.5x and a high 20s IRR for unit holders.” — Ali Hedayat, Chief Executive Officer · 2026-08-10 This event crystallizes years of underwriting discipline and fundamentally resets the company's capital position. The Ekterly exit is more than a windfall—it is a strategic pivot. The proceeds provide substantial dry powder, and management explicitly stated they are “not constrained by cash at this time,” — Ali Hedayat, Chief Executive Officer · 2026-08-10 enabling participation in meaningfully larger acquisitions than historically. The team has a proven track record of redeploying capital from such exits: the TZIELD proceeds were channeled into Orserdu 1 and 2, both of which have now recouped their initial investments ahead of schedule. CFO Zaheed Mawani reinforced the operational strength, noting that cash receipts grew 16% year-over-year to $46.5 million.Lumvoa approval and the expanding royalty portfolio
The second major catalyst was the FDA approval of Viridian's veligrotug, now branded Lumvoa. DRI made a $75 million milestone payment, partially funded through its credit facility, and will begin earning royalties in Q3 with a one-quarter lag. The asset is positioned as a differentiated thyroid eye disease therapy with both active and chronic disease data and a more convenient dosing regimen. CIO Navin Jacob remains optimistic about the launch trajectory, stating that while uptake will not be instantaneous, “Q3 will be a pivotal marker for the investment, as this is when we will fully recoup our initial capital outlay for Orserdu 2, well ahead of our original expectations.” — Navin Jacob, Chief Investment Officer · 2026-08-10 This quote, while specifically about Orserdu, highlights the portfolio's rapid cash-on-cash returns. Beyond Lumvoa, CASGEVY continues to exceed expectations, with more infusions in the first half of 2026 than all of 2025, and a recent pediatric label expansion adding ~5,500 eligible patients. The company now sees a decent probability of receiving an additional sales-based payment versus original underwriting. The pre approval segment—which now carries no Phase III risk across the entire book—remains a core strategic focus, and management expects to complete at least one transaction in the second half of 2026.Market context and the royalty thesis
Navin Jacob highlighted a broader industry tailwind:In Q2 2026, despite over 60 equity deals raising $16 billion, royalty deals totaled roughly $1.7 billion in announced value, with a trailing 12-month figure of $5.3 billion—roughly flat year-over-year despite a rebound in biotech equity markets. This validates DRI's positioning as a go-to counterparty for bespoke royalty structures. The Lumvoa approval and the Ekterly exit together demonstrate DRI's full-cycle expertise, from regulatory navigation to realized returns. The company's emphasis on pre approval assets, while avoiding consensus areas like GLP-1s, has consistently yielded counter-consensus winners. Prior quarters have laid the groundwork: as Ali noted in the March call, “we started the prior 5 years with an underleveraged balance sheet,” — Ali Hedayat, Chief Executive Officer · 2026-03-04 but the current balance sheet strength is a direct product of disciplined capital allocation and internalization synergies. With adjusted EBITDA margins tracking near 92% and guidance reaffirmed for the high end, DRI enters its next phase with a robust liquidity position, a de-risked portfolio, and a clear mandate to deploy capital at scale. The market has taken notice, and the stage is set for a transformative 12–18 months.It has been DRI's strong belief that royalty financing would become a more common or mainstay method of raising capital. Our thesis appears to be materializing.